Galectin-3, Acute Kidney Injury and Myocardial Damage in Patients With Acute Heart Failure

Horiuchi, Yu; Wettersten, Nicholas; Veldhuisen, Dirk J. van; Müeller, Christian; Filippatos, Gerasimos; Nowak, Richard M.; Hogan, Christopher; Kontos, Michael C.; Cannon, Chad; Muêller, G.; Birkhahn, Robert; Taub, Pam R.; Vilke, Gary M.; McDonald, Kenneth; Mahon, Niall; Núñez, Julio; Briguori, Carlo; Passino, Claudio; Duff, Stephen; Maisel, Alan S.; Murray, Patrick

doi:10.1016/j.cardfail.2022.09.017

Cited by 10 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study of AHF patients, who were enrolled in the acute kidney injury neutrophil gelatinase-associated lipocalin evaluation of symptomatic EF study (AKINESIS) conducted by Horiuchi et al, the authors found more common acute kidney injuries and myocardial injuries in patients with Gal-3 serum concentration > 25.9 ng/mL. In multivariable analysis, higher Gal-3 concentrations were associated with 1-year mortality [80].…”

Section: Predictor Of Prognosismentioning

confidence: 98%

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

Zaborska,

Sikora-Frąc,

Smarż

et al. 2023

IJMS

View full text Add to dashboard Cite

Heart failure (HF) is a clinical syndrome with high morbidity and mortality, and its prevalence is rapidly increasing. Galectin-3 (Gal-3) is an important factor in the pathophysiology of HF, mainly due to its role in cardiac fibrosis, inflammation, and ventricular remodeling. Fibrosis is a hallmark of cardiac remodeling, HF, and atrial fibrillation development. This review aims to explore the involvement of Gal-3 in HF and its role in the pathogenesis and clinical diagnostic and prognostic significance. We report data on Gal-3 structure and molecular mechanisms of biological function crucial for HF development. Over the last decade, numerous studies have shown an association between echocardiographic and CMR biomarkers in HF and Gal-3 serum concentration. We discuss facts and concerns about Gal-3’s utility in acute and chronic HF with preserved and reduced ejection fraction for diagnosis, prognosis, and risk stratification. Finally, we present attempts to use Gal-3 as a therapeutic target in HF.

show abstract

Section: Predictor Of Prognosismentioning

confidence: 98%